Navigation Links
Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform
Date:12/5/2012

LAUSANNE, Switzerland, December 5, 2012 /PRNewswire/ --

Biocartis launches its revolutionary detection platform, Dynamic Multi-Analyte Technology ("DMAT"):

  • New proteomic and nucleic acid platform provides ultra-high quality data analysis even at higher multiplex formats.
  • Platform launched well ahead of plan. Biocartis flips from a late-stage development company into a commercial business. 

Accurate and fast validation of biomarkers; increasing efficiency in Research and Drug Development

DMAT is an innovative and integrated detection platform for high-quality biomarker analysis. It enables accelerated development of multiplex assays where several biomarkers can be analyzed at the same time. DMAT dramatically reduces hands-on time and allows users to perform bioassays far more quickly and cost-effectively than with other systems, while ensuring optimal accuracy.

"This revolutionary technology will accelerate the conversion of biomarker discoveries into clinical practice and will help scientists deliver more quickly the promise of personalized medicine," said Biocartis CEO Dr. Greg Parekh. "DMAT is complementary with protein biomarker discovery and next generation sequencing, because the ease of use, sensitivity and accuracy enables rapid validation of new biomarkers initially identified on these other platforms."

Innovative detection technology combining reproducibility, speed and multiplexing

Conceived in 2007 and developed under design control, DMAT leverages advanced semi-conductor technologies and micro-fluidics to provide fast, flexible and multiplexed detection and quantification of nucleic acid and protein based biomarkers. The platform accelerates biomarker research and yields robust and highly reproducible data over a wide range of analyte concentrations. Demonstrating concordance between single-plex and multiplex assays, the DMAT platform can measure over 2000 analytes simultaneously without deterioration in performance.

For Research Use Only ("RUO")

The DMAT platform is initially targeting the research market. As such, Biocartis is offering customizable generic test consumables to maximize application flexibility. Biocartis is additionally developing a menu of important RUO assays including a cytokine panel, an oncogene panel and a cell signaling panel.

With the commercialization of DMAT, Biocartis is scaling up its sales force to initially target the Preclinical, Clinical Development and Clinical Research markets. 

http://www.biocartis.com


'/>"/>
SOURCE Biocartis
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer
2. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
3. Chemical Publishing Company Announces its Niche Catalog in the Water Technology and Water Treatment Space
4. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
5. The Scientist Proudly Announces the Top 10 Innovations of 2012
6. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season
7. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
8. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
9. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
10. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
11. Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... ... The recent vote by the American Medication Association to align with the World ... hopefully sheds new light on the way health insurers, governments and the public view ... of Texas Fertility Center . , “This designation is something we have ...
(Date:6/27/2017)... ... June 27, 2017 , ... Biodex Medical Systems, Inc. announces ... in one device. This assistive aid lifts patients safely from a seated to a ... lift mechanics. The Mobility Assist is the latest in a line of Biodex products ...
(Date:6/27/2017)... ... June 27, 2017 , ... Indiana-based Xylogenics announced ... production and fermentation process. The efficiencies created by the newest strain design ... notably the ethanol industry wherein individual production plants are planning to invest upwards ...
(Date:6/26/2017)... ... June 26, 2017 , ... NDA Partners Chairman ... Director of Product Development R&D at Allergan and CMC expert with more than ... and established biopharma companies, has joined the firm as an Expert Consultant. ...
Breaking Biology Technology:
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 8.8% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):